Gain Therapeutics, Inc. Forecasted to Earn Q4 2023 Earnings of ($0.28) Per Share (NASDAQ:GANX)

Gain Therapeutics, Inc. (NASDAQ:GANX – Get Rating) – Equities research analysts at HC Wainwright lifted their Q4 2023 earnings per share (EPS) estimates for Gain Therapeutics in a report released on Monday, May 15th. HC Wainwright analyst B. Pachaiyappan now forecasts that the company will earn ($0.28) per share for the quarter, up from their prior forecast of ($0.29). The consensus estimate for Gain Therapeutics’ current full-year earnings is ($1.47) per share.

Gain Therapeutics (NASDAQ:GANX – Get Rating) last released its earnings results on Thursday, March 23rd. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.02).

Separately, Chardan Capital raised their price objective on Gain Therapeutics from $4.00 to $5.75 in a research note on Monday, March 27th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $8.15.

Gain Therapeutics Stock Up 1.6 %

Shares of NASDAQ:GANX opened at $5.03 on Wednesday. The stock’s 50-day moving average price is $4.85 and its 200-day moving average price is $3.98. Gain Therapeutics has a 12-month low of $2.33 and a 12-month high of $6.19. The stock has a market capitalization of $61.16 million, a P/E ratio of -3.09 and a beta of 0.37. The company has a current ratio of 5.11, a quick ratio of 5.11 and a debt-to-equity ratio of 0.03.

Institutional Trading of Gain Therapeutics

Several large investors have recently modified their holdings of GANX. Royal Bank of Canada grew its stake in shares of Gain Therapeutics by 373.5% in the first quarter. Royal Bank of Canada now owns 50,000 shares of the company’s stock worth $205,000 after purchasing an additional 39,440 shares during the last quarter. Renaissance Technologies LLC bought a new stake in shares of Gain Therapeutics in the second quarter worth about $119,000. Raymond James & Associates bought a new stake in shares of Gain Therapeutics in the third quarter worth about $78,000. Susquehanna International Group LLP bought a new stake in shares of Gain Therapeutics in the first quarter worth about $73,000. Finally, Dimensional Fund Advisors LP bought a new stake in shares of Gain Therapeutics in the third quarter worth about $39,000. 10.21% of the stock is owned by institutional investors.

Gain Therapeutics Company Profile

(Get Rating)

Gain Therapeutics, Inc, a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease.